Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROKIDNEY CORP.PROK · Entity 5181 | Director · Chief Executive Officer | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROKIDNEY CORP.
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2036-03-01 | Direct | 3,000,000 |
Reported balance
After 2026-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 3,000,000 · Balance 3,000,000 F1: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 12:57 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 3,000,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001193125-26-086724 · ownership.xml · derivative · entry 1 Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Class A Common Stock · 3,000,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:42 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 1,796,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000950170-25-032255 · ownership.xml · derivative · entry 1 Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,796,000 Underlying: Class A Ordinary Shares · 1,796,000 shares Expires 2035-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025. Read SEC document |
| September 13, 2024 Filed Sep 16, 2024 21:31 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 500,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0000950170-24-106912 · ownership.xml · derivative · entry 1 Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Class A Ordinary Shares · 500,000 shares Expires 2033-12-03 F1 · derivative.exercise_date: This performance-based stock option was granted on December 3, 2023. On September 13, 2024, the Company's board of directors certified achievement of the performance goal at 100%. In addition to the achievement of the performance goal, the options are subject to time vesting requirements under which 25% vested on September 13, 2024 and the remaining 75% vests in equal installments of 125,000 shares on each of November 15, 2024, February 15, 2025 and May 15, 2025. Read SEC document |
| December 03, 2023 Filed Dec 5, 2023 21:04 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 2,000,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-23-057385 · doc4.xml · derivative · entry 1 Culleton Bruce · CIK 0001983742 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Class A Ordinary Shares · 2,000,000 shares Expires 2033-12-03 F1 · derivative.exercise_price: The Exercise Price is equal to the greater of (i) the thirty day average stock price of the Company's Class A Ordinary Shares on the Nasdaq Stock Market ("Nasdaq") as of the date of grant (the "Grant Date") and (ii) the closing price of the Company's Class A Ordinary Shares on Nasdaq as of the Grant Date. F2 · derivative.exercise_date: The option vests 25% on the first anniversary of November 15, 2023 and the remaining 75% vests in substantially equal quarterly installments over the following 36 months on each quarterly anniversary of November 15, 2023, subject to continued employment through each such vesting date. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 12:52 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 485,000 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001209191-23-044316 · doc4.xml · derivative · entry 1 Culleton Bruce · CIK 0001983742 · EVP, Clinical Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,000 Underlying: Class A Ordinary Shares · 485,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option vests 25% on 1st anniversary of August 1, 2023 and the remaining 75% vests in substantially equal monthly installments for 36 months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.